Increase in plasma and surface CD163 levels in patients undergoing coronary artery bypass graft surgery

Atherosclerosis

Volumn 170, Issue 2, 2003, Pages 325-332

  Goldstein, Jonathan I ^a   Goldstein, Katharine A ^a   Wardwell, Kathleen ^a   Fahrner, Scott L ^b   Goonan, Katie E ^a   Cheney, Matthew D ^a   Yeager, Mark P ^b   Guyre, Paul M ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

CABG; CD163; CPB; Glucocorticoids; Inflammation; SIRS

Indexed keywords

CD163 ANTIGEN; GLUCOCORTICOID; HAPTOGLOBIN; HEMOGLOBIN; METHYLPREDNISOLONE; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; AORTA CLAMPING; ARTICLE; CARDIOPULMONARY BYPASS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG RESPONSE; ELECTIVE SURGERY; FEMALE; HUMAN; IN VIVO STUDY; INFLAMMATION; MALE; MONOCYTE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STIMULATION; SURFACE PROPERTY; SURGICAL PATIENT; SURGICAL TECHNIQUE; TIME;

EID: 0242493006     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00297-1     Document Type: Article

References (47)

1. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
2. Hall R.I., Smith M.S., Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth. Analg. 85:1997;766-782.
3. De Bacquer D., De Backer G., Langlois M., Delanghe J., Kesteloot H., Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis. 157:2001;161-166.
4. Delanghe J., Cambier B., Langlois M.et al. Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. Atherosclerosis. 132:1997;215-219.
5. Kristiansen M., Graversen J.H., Jacobsen C.et al. Identification of the haemoglobin scavenger receptor. Nature. 409:2001;198-201.
6. Graversen J.H., Madsen M., Moestrup S.K. CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int. J. Biochem. Cell Biol. 34:2002;309-314.
7. Madsen M., Graversen J.H., Moestrup S.K. Haptoglobin and CD163: captor and receptor gating hemoglobin to macrophage lysosomes. Redox Rep. 6:2001;386-388.
8. Asleh R., Marsh S., Shilkrut M M.et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92(11):2003;1193-1200.
9. Morganelli P.M., Guyre P.M. IFN-gamma plus glucocorticoids stimulate the expression of a newly identified human mononuclear phagocyte-specific antigen. J. Immunol. 140:1988;2296-2304.
10. Sulahian T.H., Hogger P., Wahner A.E.et al. Human monocytes express CD163 which is upregulated by IL-10 and identical to p155. Cytokine. 12:2000;1312-1321.
11. Buechler C., Ritter M., Orso E., Langmann T., Klucken J., Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J. Leukoc. Biol. 67:2000;97-103.
12. Zwadlo-Klarwasser G., Schmutzler W. The effects of the glucocorticoids prednisolone, deflazacort and beclomethasone-dipropionate on the RM3/1 macrophage in human peripheral blood. Skin Pharmacol. Appl. Skin Physiol. 11:1998;227-231.
13. Schaer D.J. The macrophage hemoglobin scavenger receptor (CD163) as a genetically determined disease modifying pathway in atherosclerosis. Atherosclerosis. 163:2002;199-201.
14. Schaer D.J., Boretti F.S., Schoedon G., Schaffner A. Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel anti-inflammatory action of glucocorticoids. Br. J. Haematol. 119:2002;239-243.
15. Boheler K.R., Volkova M., Morrell C.et al. Sex- and age-dependent human transcriptome variability: Implications for chronic heart failure. Proc. Natl. Acad. Sci. U.S.A. 100(5):2003;2754-2759.
16. Moller H.J., Peterslund N.A., Graversen J.H., Moestrup S.K. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood. 99:2002;378-380.
17. Sulahian T.H., Hintz K.A., Wardwell K., Guyre P.M. Development of an ELISA to measure soluble CD163 in biological fluids. J. Immunol. Methods. 252:2001;25-31.
18. Fonseca J.E., Edwards J.C., Blades S., Goulding N.J. Macrophage subpopulations in rheumatoid synovium: reduced CD163 expression in CD4+ T lymphocyte-rich microenvironments. Arthritis Rheum. 46:2002;1210-1216.
19. Hintz K.A., Rassias A.J., Wardwell K.et al. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J. Leukoc. Biol. 72:2002;711-717.
20. Kaca W., Roth R.I., Levin J. Hemoglobin, a newly recognized lipopolysaccharide (LPS)-binding protein that enhances LPS biological activity. J. Biol. Chem. 269:1994;25078-25084.
21. Su D., Roth R.I., Yoshida M., Levin J. Hemoglobin increases mortality from bacterial endotoxin. Infect. Immun. 65:1997;1258-1266.
22. Kharazmi A., Andersen L.W., Baek L., Valerius N.H., Laub M., Rasmussen J.P. Endotoxemia and enhanced generation of oxygen radicals by neutrophils from patients undergoing cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 98:1989;381-385.
23. Andersen L.W., Baek L., Thomsen B.S., Rasmussen J.P. Effect of methylprednisolone on endotoxemia and complement activation during cardiac surgery. J. Cardiothorac. Anesth. 3:1989;544-549.
24. Karlstad M.D., Patteson S.K., Guszcza J.A., Langdon R., Chesney J.T. Methylprednisolone does not influence endotoxin translocation during cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. 7:1993;23-27.
25. Wright G. Haemolysis during cardiopulmonary bypass: update. Perfusion. 16:2001;345-351.
26. Landow L., Andersen L.W. Splanchnic ischaemia and its role in multiple organ failure. Acta Anaesthesiol. Scand. 38:1994;626-639.
27. Landow L., Phillips D.A., Heard S.O., Prevost D., Vandersalm T.J., Fink M.P. Gastric tonometry and venous oximetry in cardiac surgery patients. Crit. Care Med. 19:1991;1226-1233.
28. Paparella D., Yau T.M., Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur. J. Cardiothorac. Surg. 21:2002;232-244.
29. Hogger P., Sorg C. Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation. Biochem. Biophys. Res. Commun. 288:2001;841-843.
30. Borowitz M.J., Guenther K.L., Shults K.E., Stelzer G.T. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am. J. Clin. Pathol. 100:1993;534-540.
31. Ziegler-Heitbrock H.W. Definition of human blood monocytes. J. Leukoc. Biol. 67:2000;603-606.
32. Reiss W.G., Slaughter R.L., Ludwig E.A., Middleton E. Jr., Jusko W.J. Steroid dose sparing: pharmacodynamic responses to single versus divided doses of methylprednisolone in man. J. Allergy Clin. Immunol. 85:1990;1058-1066.
33. Al-Habet S.M., Rogers H.J. Methylprednisolone pharmacokinetics after intravenous and oral administration. Br. J. Clin. Pharmacol. 27:1989;285-290.
34. Fillinger M.P., Rassias A.J., Guyre P.M.et al. Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery. J. Cardiothorac. Vasc. Anesth. 16:2002;163-169.
35. Wei M., Kuukasjarvi P., Laurikka J.et al. Inflammatory cytokines and soluble receptors after coronary artery bypass grafting. Cytokine. 15:2001;223-228.
36. Wan S., LeClerc J.L., Vincent J.L. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 112:1997;676-692.
37. Kirklin J.K., Westaby S., Blackstone E.H., Kirklin J.W., Chenoweth D.E., Pacifico A.D. Complement and the damaging effects of cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 86:1983;845-857.
38. Sawa Y., Shimazaki Y., Kadoba K.et al. Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. J. Thorac. Cardiovasc. Surg. 111:1996;29-35.
39. Frings W., Dreier J., Sorg C. Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett. 526:2002;93-96.
40. Matsushita N., Kashiwagi M., Wait R.et al. Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin. Exp. Immunol. 130:2002;156-161.
41. Steinberg J., Fink G., Picone A.et al. Evidence of increased matrix metalloproteinase-9 concentration in patients following cardiopulmonary bypass. J. Extra Corpor. Technol. 33:2001;218-222.
42. Boeken U., Feindt P., Schulte H.D., Gams E. Elastase release following myocardial ischemia during extracorporeal circulation (ECC) - marker of ongoing systemic inflammation? Thorac. Cardiovasc. Surg. 50:2002;136-140.
43. Coyne C.P., Howell T. III, Smodlaka H., Willetto C., Fenwick B.W., Chenney E. Alterations in membrane-associated CD14 expression and the simultaneous liberation of soluble CD14 fragment in adherent macrophages mediated by a leukocyte carboxyl/aspartate protease. J. Endotoxin Res. 8:2002;273-283.
44. Le-Barillec K., Si-Tahar M., Balloy V., Chignard M. Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. J. Clin. Invest. 103:1999;1039-1046.
45. Fiore E., Fusco C., Romero P., Stamenkovic I. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene. 21:2002;5213-5223.
46. Taylor K.M., Bain W.H., Jones J.V., Walker M.S. The effect of hemodilution on plasma levels of cortisol and free cortisol. J. Thorac. Cardiovasc. Surg. 72:1976;57-61.
47. Gratchev A., Guillot P., Hakiy N.et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand. J. Immunol. 53:2001;386-392.